Short Interest in BriaCell Therapeutics Corp. (NASDAQ:BCTX) Drops By 72.8%

BriaCell Therapeutics Corp. (NASDAQ:BCTX) was the recipient of a significant drop in short interest in September. As of September 30th, there was short interest totalling 449,200 shares, a drop of 72.8% from the September 15th total of 1,650,000 shares. Based on an average trading volume of 4,780,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 1.6% of the company’s stock are sold short.

BriaCell Therapeutics Price Performance

NASDAQ:BCTX traded down $0.02 during trading hours on Friday, hitting $0.99. The company’s stock had a trading volume of 709,166 shares, compared to its average volume of 1,656,502. The stock has a fifty day simple moving average of $0.74 and a 200-day simple moving average of $1.33. BriaCell Therapeutics has a twelve month low of $0.46 and a twelve month high of $5.97. The company has a market capitalization of $35.36 million, a P/E ratio of -0.79 and a beta of 1.34.

Hedge Funds Weigh In On BriaCell Therapeutics

An institutional investor recently raised its position in BriaCell Therapeutics stock. Onyx Bridge Wealth Group LLC increased its stake in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) by 66.7% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 50,000 shares of the company’s stock after acquiring an additional 20,000 shares during the quarter. Onyx Bridge Wealth Group LLC owned about 0.31% of BriaCell Therapeutics worth $143,000 at the end of the most recent quarter. 15.42% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of BriaCell Therapeutics in a research note on Thursday, October 3rd.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.